Car T-Cell Therapy

CD19-directed chimeric antigen receptor T-cell therapies have produced unprecedented response rates among patients with advanced hematologic malignancies, yet many patients who respond to this therapy experience disease relapse.

As targeted therapies and novel treatments emerge, allogeneic hematopoietic cell transplantation has taken a backseat to immunotherapy in the treatment of lymphoma.

Peter Abdelmessieh, DO, MSc, has joined the department of bone marrow transplant and cellular therapies at Fox Chase Cancer Center.

Sarah K. Tasian, MD, has been appointed chief of the section of hematologic malignancies within the division of oncology at Children’s Hospital of Philadelphia.

In this video, John C. Byrd, MD, a professor at The Ohio State University, discussed the results of a phase 2 study that evaluated a new CAR T-cell therapy for adult patients with ALL.

Moffitt Cancer Center in Tampa has been one of the early leaders in cellular therapies for cancer treatment.

The FDA granted fast track designation to ALLO-605, a chimeric antigen receptor T-cell therapy for adults with relapsed or refractory multiple myeloma.

Patients with relapsed or refractory large B-cell lymphoma who received second-line axicabtagene ciloleucel achieved significantly longer EFS than those who received standard of care, according to data released by the agent’s manufacturer.

In the last year, the COVID-19 pandemic created panic and uncertainty for everyone, but most notably individuals with cancer and other immunosuppressing diseases, and their providers.

The last few years have yielded “incredible numbers of new drugs approved and under development” in multiple myeloma, Cristina Gasparetto, MD, director of the multiple myeloma program at Duke University, told Healio in a video interview.